Topical vapocoolant spray in reducing the pain of intravenous cannulation in the emergency department: a randomised, single-blinded, placebo-controlled trial
A randomised controlled clinical trial to compare the efficacy of pressurised vapocoolant and water sprays in decreasing the pain of intravenous cannulation in emergency department patients.
Austin Health
200 participants
Oct 1, 2007
Interventional
Conditions
Summary
Vapocollant spray is used overseas to decrease the pain of intravenous cannulation. However, no randomised controlled trial has been reported to provide evidence for this.
Eligibility
Inclusion Criteria1
- Emergency department patients, aged 18 years or more, requiring intravenous cannulation.
Exclusion Criteria1
- Refusal to provide consent; Inability to provide informed consent (Non-English speaking, altered mental state, significant illness); Moderate to severe discomfort or pain; Diseases of the skin associated with cold intolerance (eg: Raynaud’s phenomenon); Known allergy to spray contents; Peripheral neuropathy; Parenteral analgesia in the previous 4 hours
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Two second spray of pressurised vapocoolant "COLD Spray" (butane, propane, pentane blend), from 12 cm, to the IV cannulation site. The alkane blend may vary with the batch and specific proportions of the three alkanes are not available
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000470493